| Prev Close | 0.78 |
| Open | 0.72 |
| Day Low/High | 0.72 / 0.78 |
| 52 Wk Low/High | 0.44 / 1.44 |
| Volume | 96.00K |
| Avg Volume | 70.00K |
| Exchange | OTC |
| Shares Outstanding | 33.58M |
| Market Cap | 26.19M |
| EPS | -0.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs
Patents provide broad protection for the innate defense regulator technology platform
Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield® In GI ARS
Awarded $634,000 in additional contract funding
Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation
ThermoVax® Development Expands into Pandemic Infectious Disease
OTCQX And OTCQB Companies To Present At 2016 Marcum MicroCap Conference
OTC Markets Group, President and CEO R. Cromwell Coulson, will speak on panel "Understanding Reg A+ and the 'Mini IPO'"
Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
Awarded $3.2M to Conduct Preclincial Efficacy and Toxicology Studies
Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
Awarded $4.3M to Support Manufacturing Activities
Soligenix Announces Issuance Of New Patents For Dusquetide
Patents provide broad protection, including composition of matter claims
Soligenix Announces Publication Of Preclinical Efficacy Results With Dusquetide In Infectious Disease
Preclinical Results Supported by Recent Positive Phase 2 Clinical Trial
Soligenix Announces Recent Accomplishments And Year-End 2015 Financial Results
Highlighted by Revenues of $8.8 Million
Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
Awarded $660,000 to accelerate regulatory interactions with FDA
Soligenix Announces Positive Preliminary Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
Study Demonstrates Significant Reduction in Duration of Severe Oral Mucositis
Soligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma
NORD and CLF working with Soligenix to Accelerate Enrollment
Soligenix Announces Completion Of Patient Enrollment Into Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
Company on Track to Report Results in Fourth Quarter 2015
Soligenix Receives Additional NIAID Funding To Advance Development Of OrbeShield™ In GI ARS
Awarded $2.1 million in additional funding